Event
Impact of FDA Project FrontRunner on Oncology Drug Development
calendar

December 10, 2024

Calendar
clock

11:00am - 12:00pm

GMT

Register

View all IQVIA events

Discover how early access to investigational therapies can transform cancer treatment, offering patients new hope and improving clinical outcomes. IQVIA’s team of experts will discuss the advantages of early development, including enhanced drug effect assessments and easier comparisons to standard care, all within the framework of FDA’s Project FrontRunner.

Learn from IQVIA’s experts about designing robust randomized controlled trials, expanding evidence generation earlier in development to establish the benefit risk profile. We’ll also share a compelling case study on accelerating development and patient access, showcasing our innovative clinical trial strategies for success.

  • Understand the benefits of early access to investigational cancer therapies, including improved patient outcomes.
  • Learn best practices for designing robust randomized controlled trials, selecting meaningful endpoints, and ensuring evidence generation in earlier disease clinical settings.
  • Gain insights into engaging with the FDA early, leveraging the accelerated approval pathway, and successfully navigating the evolving regulatory landscape to bring novel cancer therapies to market faster.

Related solutions

Contact Us